← Browse by Condition
Medical Condition

solid tumor

Total Trials
37
Recruiting Now
37
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for solid tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — solid tumor Clinical Trials

How many clinical trials are currently recruiting for solid tumor?
ClinicalMetric currently tracks 37 actively recruiting clinical trials for solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 37. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for solid tumor?
solid tumor research spans Phase 1 (29 trials), Phase 2 (10 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a solid tumor clinical trial?
Eligibility criteria for solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
29
Phase 2
10
Top Sponsors
Sichuan Baili Pharmaceutical Co., Ltd. 4 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 3 trials
M.D. Anderson Cancer Center 2 trials
National Cancer Institute (NCI) 1 trial
Corbus Pharmaceuticals Inc. 1 trial

Recruiting Clinical Trials

NCT07489378
Recruiting
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Enrollment
4,000 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT07229638 Phase 1, Phase 2
Recruiting
A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
Enrollment
70 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06603844 Phase 1, Phase 2
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Enrollment
156 pts
Location
United States, Unite...
Sponsor
Corbus Pharmaceuticals Inc.
View Trial →
NCT05859074 Phase 1
Recruiting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Enrollment
56 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT04469530 Phase 2
Recruiting
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
Enrollment
55 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT06576037 Phase 1
Recruiting
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Enrollment
128 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT06469008 Phase 1
Recruiting
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Enrollment
21 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
NCT05166070 EARLY_Phase 1
Recruiting
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
Enrollment
24 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06526819 Phase 1, Phase 2
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
Enrollment
120 pts
Location
United States, Japan
Sponsor
Sumitomo Pharma America, Inc.
View Trial →
NCT06410092 Phase 1
Recruiting
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
Enrollment
44 pts
Location
China
Sponsor
Sound Biopharmaceuticals Ltd.
View Trial →
NCT06801002 Phase 1
Recruiting
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Enrollment
25 pts
Location
United States
Sponsor
Jabez Bioscience, Inc
View Trial →
NCT05403177
Recruiting
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Enrollment
500 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →
NCT06166888 Phase 1
Recruiting
A Study of AK131 in Patients With Advanced Solid Tumors
Enrollment
130 pts
Location
China
Sponsor
Akeso
View Trial →
NCT06493864 Phase 1
Recruiting
A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Enrollment
21 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT06646952
Recruiting
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Hua Zhu
View Trial →
NCT07327632 EARLY_Phase 1
Recruiting
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Enrollment
300 pts
Location
China
Sponsor
Innovent Biologics Technology ...
View Trial →
NCT07165132 Phase 1
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Enrollment
104 pts
Location
United States, Canad...
Sponsor
RayzeBio, Inc.
View Trial →
NCT05701306 Phase 1, Phase 2
Recruiting
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Enrollment
100 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT06619587 Phase 1
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Enrollment
410 pts
Location
United States, Austr...
Sponsor
Genentech, Inc.
View Trial →
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Location
United States, Austr...
Sponsor
Impact Therapeutics, Inc.
View Trial →
NCT05544240 Phase 1
Recruiting
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
Enrollment
20 pts
Location
Mexico
Sponsor
Williams Cancer Foundation
View Trial →
NCT05512208 Phase 2
Recruiting
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Enrollment
55 pts
Location
United States
Sponsor
University of Oklahoma
View Trial →
NCT04794972 Phase 1
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT06086522 Phase 1
Recruiting
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Enrollment
54 pts
Location
United States
Sponsor
Qualigen Theraputics, Inc.
View Trial →
NCT06956248
Recruiting
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
Enrollment
50 pts
Location
Singapore
Sponsor
National Cancer Centre, Singap...
View Trial →
NCT04196257 Phase 1
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
View Trial →
NCT07374419 Phase 1, Phase 2
Recruiting
Atamparib in Patients With Advanced Solid Tumors
Enrollment
178 pts
Location
China
Sponsor
Nerviano Medical Sciences (Sha...
View Trial →
NCT07275242 Phase 1
Recruiting
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
Enrollment
107 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT07107633 Phase 2
Recruiting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
Enrollment
90 pts
Location
China
Sponsor
Jiaxing Pharmadax Genesis Phar...
View Trial →
NCT07676903 Phase 1
Recruiting
A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors
Enrollment
170 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT05940896 Phase 1
Recruiting
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Enrollment
24 pts
Location
China
Sponsor
RemeGen Co., Ltd.
View Trial →
NCT06028724
Recruiting
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Enrollment
782 pts
Location
Italy
Sponsor
Centro di Riferimento Oncologi...
View Trial →
NCT07382544 Phase 1
Recruiting
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
Enrollment
36 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT07678970 Phase 1
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Enrollment
10 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT06873659 Phase 1
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Enrollment
96 pts
Location
China
Sponsor
Qurgen Inc.
View Trial →
NCT06515626 EARLY_Phase 1
Recruiting
Genetically Modified T Cells Treating Malignant Tumors
Enrollment
100 pts
Location
China
Sponsor
Yi Zhang
View Trial →

Related Conditions

melanoma (3) metastatic cancer (3) breast cancer (3) advanced cancer (2) metastatic breast cancer (2) solid tumor adult (2) advanced solid tumor (2) cervical cancer (2) endometrial cancer (2) gastric cancer (2) very rare tumors (1) very rare cancers (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology